GNS Healthcare said this week that it is collaborating with Bristol-Myers Squibb to create inflammation disease models using clinical and molecular information from a BMS clinical trial.
Financial terms of the agreement were not disclosed.
GNS said that clinical outcomes researchers at BMS will use its reverse-engineering and forward-simulation platform to incorporate patients' genetic information, gene expression levels, and specific blood markers into disease models that are intended to support virtual clinical trials.
The models will be used to simulate the effects of inhibiting various drug targets as well as to predict novel molecular targets that can be used to fight immuno-inflammation in specific types of patients.
In addition to this partnership, GNS is also using its platform in a collaboration with the National Cancer Institute in which it is building models of non-small cell lung cancer (BI 7/15/11) and simulating drug interactions in NCI-60 cancer cell line datasets (BI 01/28/11).
Iya Khalil, executive vice president and co-founder of GNS Healthcare, said in a statement that the partnership with BMS is "the first step in building a significantly advanced in silico research paradigm that may enable development of new therapies based directly on human data" as well as "address the needs of patients with particular genetics and molecular phenotypes."
On a much larger scale, an in silico-based effort is currently being planned in Europe in which a group of academic and commercial organizations called the Information Technology Future of Medicine consortium plans to develop infrastructure to create virtual models that help physicians tailor treatments to individual patients' genetic and physiological characteristics (BI 07/29/11).